{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-004428","form_type":"8-K","ticker":"CMPX","cik":"0001738021","company_name":"Compass Therapeutics, Inc.","filed_at":"2026-07-01T21:00:22+00:00","discovered_at":"2026-07-01T21:02:00.238919+00:00","generated_at":"2026-07-01T21:02:12.556752+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Compass Therapeutics reports tovecimig Phase 2/3 COMPANION-002 met primary endpoint; BLA filing planned","bullets":["Tovecimig + paclitaxel achieved ORR 18.0% vs 5.3% paclitaxel alone (p=0.0228); median PFS 4.7 vs 2.6 months (HR=0.44, p<0.0001).","OS analysis confounded by 54% crossover; post-hoc subset shows median OS 12.8 mo for crossover patients vs 6.1 mo for no-crossover (HR=0.54, p=0.04).","Cash and marketable securities $195M as of Q1 2026; runway into 2028. FDA meeting expected Q3 2026, BLA filing late 2026, potential approval 2H 2027.","Pipeline includes CTX-8371 (PD-1xPD-L1) with deep responses in TNBC, HL, NSCLC; CTX-471 (CD137) Phase 2 in NCAM+ tumors mid-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-004428","json":"https://secwatch.observer/filing/0001171843-26-004428.json","markdown":"https://secwatch.observer/filing/0001171843-26-004428.md","text":"https://secwatch.observer/filing/0001171843-26-004428.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326004428/0001171843-26-004428-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326004428/f8k_070126.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-01T21:02:12.556752+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}